Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 54, Issue 1 SUPPL. 1, 2009, Pages

  Barst, Robyn J ^a   Gibbs, J Simon R ^b   Ghofrani, Hossein A ^c   Hoeper, Marius M ^d   McLaughlin, Vallerie V ^e   Rubin, Lewis J ^f   Sitbon, Olivier ^g   Tapson, Victor F ^h   Galiè, Nazzareno ⁱ  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UCSD MEDICAL CENTER   (United States)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

algorithm; evidence based treatment; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; WARFARIN;

ANTICOAGULANT THERAPY; BLALOCK HANLON OPERATION; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIURETIC THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FLUID RETENTION; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HUMAN; HYPOXEMIA; LUNG TRANSPLANTATION; MONOTHERAPY; OXYGEN THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67649588196     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.017     Document Type: Review

References (57)

1. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
2. Rich S., and Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76 (1987) 135-141
3. Raffy O., Azarian R., Brenot F., et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 93 (1996) 484-488
4. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
5. Sitbon O., Humbert M., Jaïs X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
6. Yung D., Widlitz A.C., Rosenzweig E.B., Kerstein D., Maislin G., and Barst R.J. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110 (2004) 660-665
7. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
8. Frank H., Mlczoch J., Huber K., Schuster E., Gurtner H.P., and Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112 (1997) 714-721
9. Johnson S.R., Mehta S., and Granton J.T. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 28 (2006) 999-1004
10. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 112 (1990) 485-491
11. Barst R.J., Rubin L.J., Long W.A., et al., Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
12. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
13. Kerstein D., Levy P.S., Hsu D.T., Hordof A.J., Gersony W.M., and Barst R.J. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91 (1995) 2028-2035
14. Sandoval J., Rothman A., and Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 22 (2001) 547-560
15. Klepetko W., Mayer E., Sandoval J., et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 73S-80S
16. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32 (1998) 297-304
17. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
18. Langleben D., Christman B.W., Barst R.J., et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 143 (2002) E4
19. Simonneau G., Barst R.J., Galiè N., et al., Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
20. Galiè N., Humbert M., Vachiéry J.-L., et al., Arterial Pulmonary Hypertension and Beraprost European Trial (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
21. Olschewski H., Simonneau G., Galiè N., et al., Aerosolized Iloprost Randomized Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
22. Rubin L.J., Badesch D.B., Barst R.J., et al., Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
23. Barst R.J., McGoon M., McLaughlin V.V., et al., Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
24. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
25. Barst R.J., Langleben D., Frost A., et al., STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
26. Galiè N., Ghofrani H.A., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
27. Galiè N., Beghetti M., Gatzoulis M.A., et al., Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
28. Barst R.J., Langleben D., Badesch D., et al., STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
29. Galiè N., Olschewski H., Oudiz R.J., et al., Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117 (2008) 3010-3019
30. Galiè N., Rubin L.J., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 (2008) 2093-2100
31. Galiè N., Brundage B.H., Ghofrani A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) In press
32. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
33. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., and Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary hypertension. Eur Respir J 26 (2005) 858-863
34. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
35. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
36. McLaughlin V., Rubin L., Benza R., et al. TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH) (abstr). Am J Respir Crit Care Med 177 (2008) A965
37. Simonneau G., Rubin L.J., Galiè N., et al., PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530
38. Galiè N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
39. Galiè N., Manes A., Negro L., et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30 (2009) 394-403
40. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114 (1998) 787-792
41. McLaughlin V.M., Archer S.A., Badesch D.B., et al. ACCF/AHA clinical expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 53 (2009) 1573-1619
42. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 (2001) 1682-1687
43. Bowyer J.J., Busst C.M., Denison D.M., and Shinebourne E.A. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 55 (1986) 385-390
44. Keogh A., Mayer E., Benza R.L., et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 54 Suppl S (2009) S67-S77
45. McLaughlin V.V., Gaine S.P., Barst R.J., et al., Treprostinil Study Group. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
46. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129 (2006) 683-688
47. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
48. Higenbottam T.W., Butt A.Y., Dinh-Xaun A.T., Takao M., Cremona G., and Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79 (1998) 175-179
49. Galiè N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
50. Barst R.J. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 8 (2007) 95-109
51. Galiè N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
52. McLaughlin V. Long-term ambrisentan therapy for pulmonary arterial hypertension in patients who previously received placebo in ARIES-1 or ARIES-2 (abstr). Am J Respir Crit Care Med 177 (2008) A697
53. Burgess G., Hoogkamer H., Collings L., and Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 64 (2008) 43-50
54. Wrishko R.E., Dingemanse J., Yu A., Darstein C., Phillips D.L., and Mitchell M.I. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharm 48 (2008) 610-618
55. Spence R., Harrison B., Mandagere A., and Dufton C. No clinically relevant pharmacokinetic interactions between ambrisentan and tadalafil (abstr). Chest 134 (2008) 161002
56. Spence R., Mandagere A., Dufton C., and Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 48 (2008) 1451-1459
57. Coyne TC, Garces PC, Kramer W. No clinical interactions between sitaxsentan and sildenafil. Presented at the annual meeting of the American College of Rheumatology, November 2005, San Diego, CA.